Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

International Medica Foundation Sublicenses First Rotavirus Vaccine for Newborns in China

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
Vaccine to prevent deadly diarrhea in infants in China.

The International Medica Foundation announced today that it has sublicensed to Shanghai BravoBio Co., Ltd. of China, the first rotavirus vaccine that has been clinically tested for use in newborns. This will be the first time that a rotavirus vaccine will be developed for the Chinese market where the first dose of the rotavirus vaccine will be orally administered to newborns. This agreement represents a major milestone in bringing a safer and superior rotavirus vaccine to families in need globally.

Rotavirus is a vaccine preventable disease but rotavirus gastroenteritis causes an estimated 329,000 hospitalizations and 4,900 deaths in infants and children each year in China. Almost 16 million babies are born in China annually and like all newborns the world over are at risk of rotavirus infection which can cause life-threatening diarrhea.

“We are excited about our sublicense for the world’s first rotavirus vaccine for newborns and that it has superior attributes over the currently marketed rotavirus vaccines,” commented Dr. Wu Ke, President of BravoBio. “Once we obtain regulatory approval, China will lead the world in providing early protection against diarrhea caused by rotavirus in young infants.”

International Medica has been developing a rotavirus vaccine for global use to overcome the shortcomings of the currently marketed rotavirus vaccines, which do not protect very young infants, may be associated with an increased risk of vaccine associated intussusception (a blockage of the intestine which requires hospitalization), are costly and require expensive refrigerated storage. International Medica’s oral rotavirus vaccine addresses all of these problems. Based on the RRV-TV vaccine originally developed at the National Institutions of Health, International Medica has successfully completed a large safety and efficacy Phase 2 clinical trial in Africa in 998 young infants that received both doses of the vaccine before they were 2 months old. “We are very pleased that our vaccine is providing strong, early protection to infants, usually before the first dose of other rotavirus vaccines is even administered. As recently reported in the Journal of Infectious Diseases, two early doses of our RRV-TV vaccine is comparable in efficacy to three doses of other rotavirus vaccines given later to older infants,” says Dr. Leonard Ruiz, President of International Medica.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!